Surgify recently launched a new flagship surgical cutting technology.
Surgify’s technology cuts bone while preventing injuries to easily damageable soft tissues such as meninges, muscles, blood vessels, nerve pathways or central nervous system structures. Depending on the type of surgery, the risk of soft tissue damage can be up to 30%. With Surgify’s technology, such injuries can possibly be avoided entirely.
Surgify’s technology can potentially save hospitals up to €3 million a year, due to the prevention of complications and lessened need for continued care. When the soft tissue is not damaged, the patient needs less treatment, recovers faster and postoperative complications are less likely.
Surgify’s technology is suitable for both traditional handheld surgeries as well as surgical robotics.
“We see our solution as part of a bigger change that is happening in surgery, and that enables wider use of automation in many types of procedures. We envision enabling surgeons to perform their surgical skills beyond the limitations of current surgical instrumentation, allowing best-in-class surgical procedures for every patient and cost-efficient innovation for the health system,” says Surgify’s CEO, Visa Sippola.
Surgify is targeting the international market with its product.
Chair of Board, Lex R. Giltaij MD, said, “We’re starting in the Nordic countries and will soon take our groundbreaking technology to the international markets in the EU and USA.”
Surgify recently launched a new flagship surgical cutting technology.
Surgify’s technology cuts bone while preventing injuries to easily damageable soft tissues such as meninges, muscles, blood vessels, nerve pathways or central nervous system structures. Depending on the type of surgery, the risk of soft tissue damage can be up to 30%. With...
Surgify recently launched a new flagship surgical cutting technology.
Surgify’s technology cuts bone while preventing injuries to easily damageable soft tissues such as meninges, muscles, blood vessels, nerve pathways or central nervous system structures. Depending on the type of surgery, the risk of soft tissue damage can be up to 30%. With Surgify’s technology, such injuries can possibly be avoided entirely.
Surgify’s technology can potentially save hospitals up to €3 million a year, due to the prevention of complications and lessened need for continued care. When the soft tissue is not damaged, the patient needs less treatment, recovers faster and postoperative complications are less likely.
Surgify’s technology is suitable for both traditional handheld surgeries as well as surgical robotics.
“We see our solution as part of a bigger change that is happening in surgery, and that enables wider use of automation in many types of procedures. We envision enabling surgeons to perform their surgical skills beyond the limitations of current surgical instrumentation, allowing best-in-class surgical procedures for every patient and cost-efficient innovation for the health system,” says Surgify’s CEO, Visa Sippola.
Surgify is targeting the international market with its product.
Chair of Board, Lex R. Giltaij MD, said, “We’re starting in the Nordic countries and will soon take our groundbreaking technology to the international markets in the EU and USA.”
Copy to clipboard 
